senaparib   Click here for help

GtoPdb Ligand ID: 11199

Synonyms: IMP-4297 | IMP4297
Compound class: Synthetic organic
Comment: Senaparib (IMP4297) is an oral poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [1] that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 104.19
Molecular weight 478.16
XLogP 3.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1C(=O)N1CCN(CC1)c1ncccn1)Cn1c(=O)[nH]c(=O)c2c1cccc2F
Isomeric SMILES Fc1ccc(cc1C(=O)N1CCN(CC1)c1ncccn1)Cn1c(=O)[nH]c(=O)c2c1cccc2F
InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35)
InChI Key VBTUJTGLLREMNW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE. (2024)
The discovery of a potent PARP1 inhibitor Senaparib.
Mol Cancer Ther, [Epub ahead of print]. [PMID:38920409]
2. Cai SX, Tian YE, Dong H, Xu Q, Wu L, Liu L, Jiang Y, Bao , Wang G, Yin F et al.. (2012)
1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof.
Patent number: WO2012130166A1. Assignee: Impact Therapeutics, Inc.. Priority date: 01/04/2011. Publication date: 04/10/2012.
3. Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y et al.. (2024)
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Nat Med, 30 (6): 1612-1621. [PMID:38750351]